EE05172B1 - Mesoprogestiinid (progesterooniretseptori modulaatorid) healoomuliste hormoons?ltuvate gnekoloogiliste haiguste raviks ja v„ltimiseks - Google Patents

Mesoprogestiinid (progesterooniretseptori modulaatorid) healoomuliste hormoons?ltuvate gnekoloogiliste haiguste raviks ja v„ltimiseks

Info

Publication number
EE05172B1
EE05172B1 EEP200200104A EEP200200104A EE05172B1 EE 05172 B1 EE05172 B1 EE 05172B1 EE P200200104 A EEP200200104 A EE P200200104A EE P200200104 A EEP200200104 A EE P200200104A EE 05172 B1 EE05172 B1 EE 05172B1
Authority
EE
Estonia
Prior art keywords
mesoprogestins
prevention
treatment
receptor modulators
progesterone receptor
Prior art date
Application number
EEP200200104A
Other languages
English (en)
Estonian (et)
Inventor
Chwalisz Kristof
Elger Walter
Schubert Gerd
Original Assignee
Jenapharm Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg
Publication of EE200200104A publication Critical patent/EE200200104A/xx
Publication of EE05172B1 publication Critical patent/EE05172B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
EEP200200104A 1999-08-31 2000-08-31 Mesoprogestiinid (progesterooniretseptori modulaatorid) healoomuliste hormoons?ltuvate gnekoloogiliste haiguste raviks ja v„ltimiseks EE05172B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31
PCT/US2000/023770 WO2001015679A2 (en) 1999-08-31 2000-08-31 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders

Publications (2)

Publication Number Publication Date
EE200200104A EE200200104A (et) 2003-04-15
EE05172B1 true EE05172B1 (et) 2009-06-15

Family

ID=23524338

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200104A EE05172B1 (et) 1999-08-31 2000-08-31 Mesoprogestiinid (progesterooniretseptori modulaatorid) healoomuliste hormoons?ltuvate gnekoloogiliste haiguste raviks ja v„ltimiseks

Country Status (34)

Country Link
EP (1) EP1229906B1 (https=)
JP (1) JP2003535029A (https=)
KR (3) KR20080066095A (https=)
AR (1) AR025457A1 (https=)
AT (1) ATE375160T1 (https=)
AU (1) AU781840B2 (https=)
BG (1) BG65817B1 (https=)
BR (1) BR0014161A (https=)
CA (1) CA2382580C (https=)
CO (1) CO5200772A1 (https=)
CZ (1) CZ2002704A3 (https=)
DE (1) DE60036723T2 (https=)
DK (1) DK1229906T3 (https=)
EA (1) EA007854B1 (https=)
EE (1) EE05172B1 (https=)
ES (1) ES2295050T3 (https=)
HR (1) HRP20020267A2 (https=)
HU (1) HUP0202429A3 (https=)
IL (1) IL148416A0 (https=)
LT (1) LT5034B (https=)
LV (1) LV12941B (https=)
ME (1) MEP13808A (https=)
MX (1) MXPA02002191A (https=)
NO (1) NO20020999L (https=)
NZ (1) NZ517471A (https=)
PE (1) PE20010578A1 (https=)
PL (1) PL198790B1 (https=)
PT (1) PT1229906E (https=)
RO (1) RO122179B1 (https=)
RS (1) RS50283B (https=)
SI (1) SI20852B (https=)
SK (1) SK287192B6 (https=)
UA (1) UA78184C2 (https=)
WO (1) WO2001015679A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003255355A1 (en) * 2002-08-02 2004-02-25 Schering Aktiengesellschaft Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2301691C1 (ru) * 2005-12-20 2007-06-27 Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
RU2339392C1 (ru) * 2007-05-21 2008-11-27 Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий Способ остановки маточных кровотечений в пубертатном периоде
JP4709328B2 (ja) * 2009-06-17 2011-06-22 国立大学法人 熊本大学 月経困難症の予防及び/又は治療薬
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
JP2022548314A (ja) * 2019-09-23 2022-11-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5696127A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
EP1043325B1 (en) * 1994-12-22 2004-06-16 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
UA37259C2 (uk) 1995-02-02 2001-05-15 Шерінг Актієнгезеллшафт Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1144396A2 (en) * 1999-01-14 2001-10-17 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
HK1043788A1 (zh) * 1999-05-04 2002-09-27 American Home Products Corporation 四環黃體酮受體調節劑化合物及方法

Also Published As

Publication number Publication date
ATE375160T1 (de) 2007-10-15
PL353930A1 (en) 2003-12-15
CA2382580C (en) 2009-05-19
PT1229906E (pt) 2008-01-18
RS50283B (sr) 2009-09-08
KR20070058023A (ko) 2007-06-07
HUP0202429A3 (en) 2004-04-28
LT5034B (lt) 2003-07-25
WO2001015679A3 (en) 2001-11-22
UA78184C2 (en) 2007-03-15
MEP13808A (en) 2010-06-10
JP2003535029A (ja) 2003-11-25
SI20852A (sl) 2002-10-31
DE60036723D1 (de) 2007-11-22
EE200200104A (et) 2003-04-15
AU781840B2 (en) 2005-06-16
KR20020027616A (ko) 2002-04-13
ES2295050T3 (es) 2008-04-16
KR100864547B1 (ko) 2008-10-20
NZ517471A (en) 2004-02-27
DK1229906T3 (da) 2008-02-11
EA200200282A1 (ru) 2002-10-31
WO2001015679A2 (en) 2001-03-08
CZ2002704A3 (cs) 2003-02-12
AU6946600A (en) 2001-03-26
PE20010578A1 (es) 2001-06-04
CA2382580A1 (en) 2001-03-08
CO5200772A1 (es) 2002-09-27
NO20020999L (no) 2002-03-14
YU14002A (sh) 2006-01-16
DE60036723T2 (de) 2008-07-17
BG65817B1 (bg) 2010-01-29
SK287192B6 (sk) 2010-02-08
HUP0202429A2 (en) 2002-10-28
BR0014161A (pt) 2002-05-21
EA007854B1 (ru) 2007-02-27
KR100755109B1 (ko) 2007-09-04
EP1229906A2 (en) 2002-08-14
AR025457A1 (es) 2002-11-27
NO20020999D0 (no) 2002-02-28
BG106442A (bg) 2002-09-30
MXPA02002191A (es) 2002-09-30
EP1229906B1 (en) 2007-10-10
RO122179B1 (ro) 2009-02-27
PL198790B1 (pl) 2008-07-31
SK2992002A3 (en) 2002-07-02
LT2002031A (en) 2003-02-25
SI20852B (sl) 2009-06-30
IL148416A0 (en) 2002-09-12
HRP20020267A2 (en) 2004-04-30
LV12941B (en) 2003-06-20
KR20080066095A (ko) 2008-07-15

Similar Documents

Publication Publication Date Title
DE69807634D1 (de) Medizinische einrichtung zur verabreichung von therapeutischen wirkstoffen
NO20020912D0 (no) Bicykliske androgen- og progesteronreseptorer- modulatorforbindelser og fremgangsmåter
NO20024478D0 (no) Hormonerstatningsterapi ved anvendelse av kombinasjon av konjugerte östrogener og medroksyprogesteronacetat
IS1886B (is) Stjórnuð losun stera úr sykruhúðum
CY2009015I2 (el) Φαρμακευτικος συνδυασμος αιθινυλεστραδιολης και δροπιρενονης για χρηση ως αντισυλληπτικο
DE69942928D1 (de) Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
NO20014379D0 (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
DK2455083T3 (da) Farmaceutisk sammensætning til dermal anvendelse omfattende calcipotriol og betamethason til behandling af psoriasis
NO20004935D0 (no) Anordning til den transdermale avleveringen av diklofenak
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
NO20005885D0 (no) Kombinasjonsterapi for behandling av refraktær depresjon
AU4134101A (en) Hormone receptor functional entities and methods of their use
EE05172B1 (et) Mesoprogestiinid (progesterooniretseptori modulaatorid) healoomuliste hormoons?ltuvate gnekoloogiliste haiguste raviks ja v„ltimiseks
NO20010468L (no) Anvendelse av biogene østrogensulfamater til hormonerstatningsterapi
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
AU5025300A (en) Compositions for controlled release of the hormone gnrh and its analogs
NO20003229L (no) Kombinasjon av benzosykloheptapyridinforbindelser og antineoplastiske midler for behandling av proliferaktive sykdommer
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
NO20014049L (no) Kontrollert frigjörings-formulering for behandling av COPD
NO20011537D0 (no) Kjemokinreseptorpeptidvaksiner for behandling og forebygging av diabetes
HUP0202741A3 (en) Pharmaceutical composition available for the therapeutic management of endometriosis and fallopian tube obstruction and process for its preparation
NO991164D0 (no) Farmas°ytisk preparat for behandling av virussykdommer
DE60032655D1 (de) Einrichtung zur Chirurgie der Hornhaut
NO20023841D0 (no) Anvendelse av glukokortikoidreseptorantagonister for forebygging og behandling av sykdommer av reproduksjonssystemethos menn

Legal Events

Date Code Title Description
HD1A Correction of address
GB1A Change in the ownership or in the address of the owner
HB1A Correction of owner name or address
HH1A Change of representative
HC1A Change of owner name
HE1A Change of address
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20100831